Navigation Links
Icahn Asks Amylin to Allow Discussions With Eastbourne
Date:4/23/2009

NEW YORK, April 23 /PRNewswire/ -- Carl Icahn announced today that he had sent the following letter to James Wilson, Lead Independent Director of Amylin Pharmaceuticals, Inc. (Nasdaq: AMLN).

                                        April 23, 2009

    Mr. James Wilson
    Lead Independent Director
    Amylin Pharmaceuticals, Inc.
    9360 Towne Centre Drive
    San Diego, CA  92121

    Dear Jim:

    If you are really serious about settling what you consider a debilitating
    proxy contest, I believe it is mandatory for you to take the necessary
    action to allow Eastbourne and myself to talk without the threat of your
    poison pill and Section 203 preventing these discussions.  It is almost
    absurd that I and Eastbourne, separately, have had to ask you a number of
    times during last week and the week before to get permission to have these
    talks.  As I have said, even in a dictatorship parties that disagree with
    the ruling regime are allowed to talk to each other.  But not at Amylin.

    I sincerely believe that as a result of these discussions and subsequent
    discussions among the three of us, there will be enough common ground to
    resolve the matter.  What exactly are you afraid of?  The alternative is
    for the Company and its stockholders to continue to be distracted because
    of the inexplicable intransigence of the current Board which continues to
    evidence itself in so many ways, e.g. the poison pill, the poison puts,
    and the failure to heed the views of your co-founder, Howard E. Greene,
    Jr., regarding Joseph Cook's board seat.

    I look forward to your prompt response.

                                        Sincerely,

                                        Carl Icahn

SECURITY HOLDERS ARE ADVISED TO READ THE PROXY STATEMENT AND OTHER D
'/>"/>

SOURCE Carl Icahn
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Icahn Responds to Cornelius
2. Icahn Confirms Intention to Nominate Three Directors at Biogen
3. Amylin Pharmaceuticals Provides Shareholders with Update Regarding Recent Developments
4. Amylin Pharmaceuticals to Present at Cowen and Company Annual Health Care Conference
5. Amylin Pharmaceuticals Confirms Receipt of Director Nomination Notices
6. Amylin Pharmaceuticals Appoints Vincent Mihalik Senior Vice President, Sales and Marketing and Chief Commercial Officer
7. Amylin Pharmaceuticals Highlights 2009 Value Creation Opportunities
8. Amylin Pharmaceuticals Announces Strategic Restructuring and Workforce Reduction
9. Amylin Pharmaceuticals to Present at BIOCOM Investor Conference
10. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
11. Amylin Pharmaceuticals Reports Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... 18, 2014 BioPlus Specialty ... specialty pharmacies, has an expanded team of Regional ... consultants for prescriber offices in their regions, with ... “We have a variety of Regional Pharmaceutical Care ... specializing in hepatitis C help prescribers understand all ...
(Date:12/19/2014)... December 18, 2014 iLab Solutions, the ... appointment of Siri Bryant as the new Director of ... of Core Implementations. These two new leadership positions were ... service by ensuring that iLab continues to meet the ... last four years, iLab has been deployed at over ...
(Date:12/19/2014)... Egenix, Inc. is pleased to announce that ... Board, to succeed Donald Fresne ; Mr. Fresne has ... a member of the Board.  In recognition of the many ... over almost twenty years, the Board designated Mr. Fresne as ... established a Search Committee to find a suitable replacement with ...
(Date:12/17/2014)... “Never say, ‘I cannot do ... Department of Physics, advises young women pursuing careers ... SPIE Women in Optics 18-month planner ... ask questions.” , In the annual planner, women ... ranging from university professor and laboratory researcher to ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 2BioPlus Specialty Pharmacy Expands ‘Regional Pharmaceutical Care Liaison’ Team 3iLab Solutions Announces Two New Leadership Positions to Meet the Needs of Its Growing Customer Base 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 2Network, Multitask, Persevere: SPIE Women in Optics Planner Subjects Share from Experience 3
... 10 /PRNewswire-FirstCall/ - Oncothyreon Inc.,(Nasdaq: ONTY ) ... PX-478, pharmacodynamic studies of PX-12 and preclinical studies ... of the American Association,for Cancer Research (AACR) in ... currently conducting a Phase 1 clinical trial of ...
... April 10 Advanced Life Sciences,Holdings, Inc. (Nasdaq: ... a productive,meeting with the U.S. Food and Drug ... Drug Application (NDA) in the third quarter of ... treat mild-to-moderate,community acquired pneumonia (CAP)., (Logo: ...
... Becoming a Global Leader in ... ... 10 ,Takeda Pharmaceutical Company Limited ("Takeda", TSE: 4502) and Millennium,Pharmaceuticals, Inc. ... definitive agreement pursuant to which Takeda will acquire,Millennium for approximately $8.8 ...
Cached Biology Technology:Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 2Oncothyreon announces data from multiple small molecule programs to be presented at American Association of Cancer Research Annual Meeting 3Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin 2Advanced Life Sciences Announces Plan to Submit NDA for Cethromycin 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 2Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 3Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 4Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 5Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 6Takeda to Acquire Millennium for US$25.00 Per Share in an All Cash Tender Offer Valued at $8.8 Billion 7
(Date:12/11/2014)... DUBLIN , Dec. 09, 2014 Research ... http://photos.prnewswire.com/prnh/20130307/600769 ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) ... Market in India 2015-2019" report to their ... in this market is the adoption of multimodal ... one characteristic of an individual for verification and ...
(Date:12/10/2014)... N.C. , Dec. 9, 2014  Wake Forest Baptist ... education building for its School of Medicine. Funding for ... larger capital campaign that will be publicly launched next ... be located in the former 60 series R.J. Reynolds ... Innovation Quarter. Construction will begin immediately with plans to ...
(Date:12/5/2014)...  Tute Genomics, a leader in cloud-based solutions for ... funding led by UK-based Eurovestech. Peak Ventures and a ... round. "We are at a pivotal time ... and seeks new approaches for the diagnosis, treatment and ... MBA, and CEO of Tute Genomics. "One of the ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 2Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 3Wake Forest Baptist to Build New Medical Education Facility In Wake Forest Innovation Quarter 4Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 2Tute Genomics Raises $2.3 Million to Scale Up Cloud-Based Genome Analytics and Accelerate Personalized Medicine 3
... and Biomedical Innovation, studied the socioenvironmental drivers of suicide rates ... coupled with spikes in unemployment were significant risk factors for ... has helped to pinpoint who and when people might be ... that when the difference of the monthly average temperature in ...
... recent years that asthma comes in several variations, with ... These subtypes of asthma can be identified by knowing ... in patients, airways. That information can, in turn, help ... inspire research to better understand, manage, and possibly prevent ...
... to drive people daffy. It,s one of the smallest and ... ponds and small lakes. But it,s also been exploited to ... Now, the genome of Greater Duckweed ( Spirodela polyrhiza ) ... a big boost. In a paper published February 19, 2014 ...
Cached Biology News:Climate change linked to increase in Australia's suicide rates: QUT study 2Pond-dwelling powerhouse's genome points to its biofuel potential 2Pond-dwelling powerhouse's genome points to its biofuel potential 3Pond-dwelling powerhouse's genome points to its biofuel potential 4
... Dithiothreitol, 1 g. High ... convenient sample preparation that give ... disrupt cells and tissues.Clean up ... sample volumes. Accurately quantitate protein ...
IMAGEQUANT 300 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
ANTI MYCOBACTERIUM TUBERCULOSIS...
IMAGEQUANT 100 WKSTN, 1 EA. Category: ImageQuant CCD Imagers....
Biology Products: